Day: February 2, 2024

SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,695,312 shares of common stock at a public offering price of $64.00 per share and pre-funded warrants to purchase 781,250 shares of common stock at a public offering price of $63.999 per underlying share. This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $862.5 million, before...

TORONTO, Feb. 02, 2024 (GLOBE NEWSWIRE) — Topicus.com Inc. (TSXV:TOI) (the “Company”) announced today that the release of its fourth quarter results will be rescheduled. The Company will defer the release of its results from the originally planned date of February 6, 2024 in order to allow the Company’s external auditors to complete their final normal course audit procedures. The Company’s quarterly results are expected to be disseminated via press release and made available on the Company’s website (www.topicus.com) and SEDAR, after markets close on Tuesday, February 13, 2024.   About Topicus.com Inc. Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol “TOI”. Topicus acquires, manages and builds vertical market software businesses. Contact: Jamal BakshChief Financial...

Wemade today announced that Estonian game developer DevDream House OÜ will be launching Multiplayer Turn-based strategy game “RoboHero” on the world’s biggest blockchain game platform, WEMIX PLAY Singapore , Feb. 02, 2024 (GLOBE NEWSWIRE) —One of the first mobile games with an ecosystem designed to bridge the Web2 and Web3 worlds Set in an immersive metaverse, Robot Factions intensely battle for control over vital resources in a post apocalyptic world Tokens and NFTs are seamlessly integrated into the gameplay, with unique DeFi tools offering a new dimension in Web3 gamingLeading global game developer Wemade today announced that Estonian game developer DevDream House OÜ will be launching Multiplayer Turn-based strategy game “RoboHero” on the world’s biggest blockchain game platform, WEMIX PLAY (www.wemixplay.com). Set...

MEMPHIS, Tenn., Feb. 02, 2024 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO), the leading retailer and distributor of automotive replacement parts and accessories in the Americas, will release results for its second quarter ended Saturday, February 10, 2024, before market open on Tuesday, February 27, 2024. Additionally, the Company will host a one-hour conference call on Tuesday, February 27, 2024, beginning at 10:00 a.m. (ET), to discuss the results of the quarter. This call is being webcast and can be accessed, along with supporting slides, at AutoZone’s website at www.autozone.com and clicking on Investor Relations. Investors may also listen to the call by dialing (888) 506-0062, passcode AUTOZONE. In addition, a telephone replay will be available by dialing 877- 481-4010, replay passcode 49727 through March 12, 2024. About...

BOSTON, Feb. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 1,600 shares of its common stock and restricted stock unit awards covering an aggregate of 1,450 shares of its common stock to two new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment...

HANGZHOU, China, Feb. 02, 2024 (GLOBE NEWSWIRE) — Kaixin Auto Holdings (“Kaixin” or the “Company”) (NASDAQ: KXIN), a leading new energy vehicle manufacturer and sales platform in China, today announced that it will hold its annual general meeting of shareholders (the “AGM”) at 198 Qidi Road, Unit B2-303-137, Beigan Community, Xiaoshan District, Hangzhou, Zhejiang Province, China on March 4, 2024 at 10:00 a.m. (Beijing time), for the purposes of considering and, if thought fit, passing and approving the resolutions set forth in the Notice of Annual General Meeting and Proxy of the Company. The board of directors of the Company has fixed the close of business on February 2, 2024 (Beijing time) as the record date (the “Record Date”) of ordinary shares. Holders of record of ordinary shares of the Company as of the Record Date are entitled...

SALT LAKE CITY, UT, Feb. 02, 2024 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced the closing of its previously announced public offering of 16,000,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, one Class E Warrant with each warrant to purchase one share of common stock, and one Class F Warrant with each warrant to purchase one share of common stock. Each unit was sold at a public offering price of $0.25. The Class E and Class F Warrants in the units are immediately exercisable at a price of $0.25 per share. The Class E Warrants will expire five years from the date of issuance and the Class F Warrants will expire eighteen months...

GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) — NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of...